Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	MRÁZ Marek ONDRIŠOVÁ Laura ŠEDA Václav HOFERKOVÁ Eva CHIODIN G. HLAVÁČ Kryštof KOŠŤÁLOVÁ Lenka MLADONICKÁ PAVLASOVÁ Gabriela FILIP Daniel ZENI Pedro OPPELT Jan PANOVSKÁ Anna PLEVOVÁ Karla POSPÍŠILOVÁ Šárka ŠIMKOVIČ M. VRBACKÝ F. LYSÁK Daniel FERNANDES SM. DAVIDS A. MAIQUES-DIAZ A. CHARALAMPOPOULOU S. MARTIN-SUBERO J. BROWN J. DOUBEK Michael FORCONI F. MAYER Jiří
Year of publication	2023
Type	Conference abstract
MU Faculty or unit	Central European Institute of Technology
Citation
Description	In this interview, Marek Mráz, PhD, Central European Institute of Technology, Brno, Czech Republic, outlines a study on resistance of chronic lymphocytic leukemia (CLL) to BCR inhibitor therapy through increased activity of the FoxO1-Rictor-pAkt axis. This highlights the potential of FoxO1 as a novel therapeutic target, with testing of a FoxO1 inhibitor in vitro showing its ability to kill CLL cells.This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
Related projects:	ÚLOHA MICRORNA A JEJICH CÍLOVÝCH MOLEKUL V TRANSFORMACI FOLIKULÁRNÍHO LYMFOMU A AGRESIVITĚ CHRONICKÉ LYMFOCYTÁRNÍ LEUKÉMIE Signaling propensity in the microenvironment of B cell chronic lymphocytic leukemia National institute for cancer research Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X